Maintenance of Drug-Eluting Stent Patency Through Use of a Cangrelor Infusion in the Clinical Setting of Massive Pulmonary Hemorrhage and Venoarterial Extracorporeal Membrane Oxygenation

Maintenance of Drug-Eluting Stent Patency Through Use of a Cangrelor Infusion in the Clinical Setting of Massive Pulmonary Hemorrhage and Venoarterial Extracorporeal Membrane Oxygenation: THE USE OF an ultrashort-acting parenteral P2Y12 inhibitor, cangrelor, for the maintenance of fresh drug-eluting stent (DES) patency in a patient with concurrent pulmonary hemorrhage and cardiogenic shock requiring central veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is described. The current standard of care for use of antiplatelet agents after percutaneous coronary intervention (PCI) with DES placement in acute coronary syndrome includes indefinite use of aspirin and 12 months of P2Y12 inhibitor to avoid in-stent thrombosis.

from ! Medicine by Alexandros G. Sfakianakis via Αλέξανδρος Σφακιανάκης on Inoreader http://ift.tt/2tEAO56
via IFTTT